Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

02. April 2026 16:30 ET | Quelle: Regeneron Pharmaceuticals, Inc.

Regeneron Collaborates with TriNetX to Access De-Identified Electronic Health Records of 300 Million Patients to Drive Research and Product Development in Life Sciences and Digital Health Solutions

Regeneron has exclusive opportunity to connect large-scale genomic and proteomic data cohorts to TriNetX’s industry-leading global network of electronic health record data Collaboration will expand...
02. April 2026 12:00 ET | Quelle: Regeneron Pharmaceuticals, Inc.

EYLEA HD® (aflibercept) Approved by FDA as First and Only Injectable Anti-VEGF with Dosing Intervals Up to 5 Months for Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME)

Approval is based on 96-week data from 2 pivotal trials showing majority of EYLEA HD patients maintained their visual and anatomic improvements with extended dosing intervals New EYLEA HD dosing...
02. April 2026 11:49 ET | Quelle: Research and Markets

Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Intelligence Report 2026-2030: Industry Growth Driven by Personalized Treatment Adoption

Dublin, April 02, 2026 (GLOBE NEWSWIRE) -- The "Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Report 2026" has been added to ResearchAndMarkets.com's offering. The report offers a...
02. April 2026 11:39 ET | Quelle: Research and Markets

Stomach Cancer Market Insights, Trends and Innovations Worldwide, 2026-2030 & 2035

Dublin, April 02, 2026 (GLOBE NEWSWIRE) -- The "Stomach Cancer Market Report 2026" has been added to ResearchAndMarkets.com's offering. This report provides insights into market dynamics, trends,...
02. April 2026 11:34 ET | Quelle: Research and Markets

Throat Cancer Market Trends and Breakthroughs Through 2026-2030 & 2035 Driven by Precision Oncology

Dublin, April 02, 2026 (GLOBE NEWSWIRE) -- The "Throat Cancer Market Report 2026" has been added to ResearchAndMarkets.com's offering. The throat cancer market has exhibited significant growth...
02. April 2026 10:18 ET | Quelle: Research and Markets

Adrenocortical Carcinoma Market Report 2026: Innovative Therapies Set to Transform the $4 Billion Adrenocortical Carcinoma Landscape

Dublin, April 02, 2026 (GLOBE NEWSWIRE) -- The "Adrenocortical Carcinoma Market Report 2026" has been added to ResearchAndMarkets.com's offering. The adrenocortical carcinoma market is on a...
01. April 2026 17:00 ET | Quelle: Adagene Inc.

Adagene Reports Full Year 2025 Financial Results and Provides Corporate Update

In 2025, muzastotug showed 29% confirmed overall response rate (ORR) among 21 patients with MSS CRC in the 20 mg/kg dose cohorts Median overall survival (OS) for the 10 mg/kg cohorts was 19.4...
31. März 2026 01:00 ET | Quelle: Sanofi Winthrop Industrie

Communiqué de presse : Le Rezurock de Sanofi approuvé dans l’UE pour le traitement de la maladie chronique du greffon contre l’hôte

Le Rezurock de Sanofi approuvé dans l’UE pour le traitement de la maladie chronique du greffon contre l’hôte Rezurock est maintenant approuvé dans l’UE pour les adultes et les enfants âgés de 12 ans...
31. März 2026 01:00 ET | Quelle: Sanofi Winthrop Industrie

Press Release: Sanofi’s Rezurock approved in the EU to treat chronic graft-vs-host disease

Sanofi’s Rezurock approved in the EU to treat chronic graft-vs-host disease Rezurock is now approved in the EU for adults and children aged 12 years and older with chronic GVHD, providing a new...
30. März 2026 08:30 ET | Quelle: Transcenta

Transcenta Therapeutics Appoints Dr. Christopher Hwang as Head of Global Partnerships for HiCB Platform

PRINCETON, N.J. and SUZHOU, China, March 30, 2026 (GLOBE NEWSWIRE) -- Transcenta Therapeutics (HKEX: 06628), a global clinical stage biopharmaceutical company with fully-integrated capabilities in...

Nächste Seite